קישור בעברית בתחתית העמוד
Another achievement for Hadasit Bio Holdings
Thrombotech, a subsidiary of Hadasit Bio Holdings, completed its Phase I trial successfully
Israel, Jerusalem, 24 August 2010 Hadasit Bio Holdings Company (Tel Aviv: HDST), announced today that its subsidiary, Thrombotech, (24% held) completed its Phase I trial successfully.
According to Hadasit CEO Ophir Shahaf: "We are pleased with Thrombotech’s results and believe it is a significant step for the company and for all companies held by Hadasit. Thrombotech’s product line promises great potential in the development of a treatment for stroke, myocardial infarction (MI), embolisms and chronic lung diseases - diseases with billion dollar markets. “
The trial was conducted at the Hadassah Ein Kerem Hospital clinical trials unit and included 40 volunteers who were treated with increasing doses of the material. No adverse events were observed using the estimated effective doses. The trial analysis is expected to be completed sometime in August – September. The results will enable the company to begin making preparations for the phase II experiments in stroke patients.
While completing the phase I clinical trial, Thrombotech began planning for its next clinical trial in stroke patients. The trial will take place in approximately 4 clinical centers in Israel and abroad and should include around 20 patients. Part of the trial will be performed in cooperation with a foreign company that Thrombotech has been in negotiations with.
Thrombotech has also been continuing with its business development activities and is in contact with two prominent investors/ financial instetutions. In addition, Thrombotech filed another patent application based on the initial finding that the peptide (short protein-based drug) developed by Thrombotech, may decrease blood pressure and improve the management of ailments related to high blood pressure - one of the world's largest markets.
Thrombotech is currently preparing for an internal round of funding from its existing shareholders.
Thrombotech’s compound is based on research by Professor Abdel Raouf Hijazi from Hadassah Ein Kerem and the University of Pennsylvania. The company was established and operates in Hamamat Nayot (owned by Ofer Hi -Tech) and is, as stated, one of Hadasit Bio holdings’ eight portfolio companies. Other major investors are Clal Biotechnology Industries (CBI) and Ofer Hi-Tech (OHV). The company is managed by Dr. Isaac Lamensdorf and chaired by Professor Marian Gorcaki.
About Hadasit Bio Holdings:
Hadasit Bio Holdings (TASE: HDST) was founded and floated by Hadasit (Hadassah Hospitals’ technology transfer company) in 2006 with the aim of promoting and commercializing the knowledge and experience gained in the research laboratories of the Hadassah Hospitals. Hadasit Bio Holdings has significant holdings in eight biotech companies all of which have successfully demonstrated feasibility and effectiveness in animal models and 4 of which are in clinical trials in humans.
All companies held by HBL are addressing Belockbuster markets and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells, areas where the Hadassah hospital has vast knowledge and is recognized as a global leader. The company is managed by Ophir Shahaf Adv.
For more information, please visit: www.hbl.co.il